NCT04821856View on ClinicalTrials.gov

Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

July 9, 2025

Study Completion Date

August 19, 2025

Conditions
Intellectual DisabilityChild Behavior Problem
Interventions
DRUG

Cannabidiol Oil

Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma

DRUG

Placebo

MCT oil and flavoring solution, also manufactured by THC Pharma

Trial Locations (3)

2145

The Children's Hospital at Westmead, Westmead

3052

Royal Children's Hospital / Murdoch Children's Research Institute, Parkville

3168

Monash Children's Hospital, Clayton

Sponsors
All Listed Sponsors
collaborator

Monash University

OTHER

collaborator

University of Sydney

OTHER

collaborator

Deakin University

OTHER

lead

Murdoch Childrens Research Institute

OTHER